Edema Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Participant (Pediatrics, Adults, Geriatrics), By Sponsor, By Type, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global edema clinical trials market size was valued at USD 830.0 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.71 % from 2023 to 2030. The rising burden of edema associated with underlying conditions such as heart failure, kidney conditions, and liver cirrhosis is a key growth driver for this market. Furthermore, growing healthcare expenditure and advancements in medical research are some of the other factors driving market growth.

The increasing geriatric population is anticipated to create growth opportunities for the market in the coming years. Edema is more prevalent among older persons, and with the global population aging, the incidence of edema is expected to rise. Approximately 771 million people worldwide, or about 10% of the world's population, will be over 65 years of age in 2022. This segment has been expanding at a rising rate, and in 2050 it is anticipated to reach 16%. This increasing population trend has contributed to the focus on edema research and clinical trials.

Additionally, the increased number of research studies being conducted related to Edema is also expected to drive market growth. For instance, in August 2021, Novartis announced successful outcomes from Beovu Phase III studies for diabetic macular edema, with dose intervals of up to 16 weeks.Results from week 100 of year two of KITE showed that the majority of the patients who effectively completed the loading phase and the initial 12-week cycle were kept on a 12- or 16-week dosing interval through the completion of the study.

The increasing demand for innovative and novel therapies is another significant driver that boosts the market for Edema clinical trials. Currently, novel diabetic retinopathy (DR) and diabetic macular edema (DME) therapies under investigation include activators of nitric oxide/cyclic GMP signaling pathways, inducers of antioxidant gene expression, erythropoietin-derived peptides, and manipulation of arginase activity.Demand for clinical trials to test these medicines rises as novel therapeutic modalities are sought to address the unmet medical requirements of edema patients.

Furthermore, rising funding for research and development projects targeted for novel edema is also expected to create demand for market growth. For instance, in June 2023, the National Institutes of Health (NIH) approved USD 2.4 million in funding to study the relationship between obesity and lymphatic dysfunction. In order to develop a therapeutic treatment for persons with lymphedema, researchers at Tulane University are investigating the relationship between inflammatory disorders and lymphatic system failure.

Phase Insights

The Phase II segment dominated the edema clinical trials market with a revenue share of around 35.71% in 2022. Phase 2 studies are designed to evaluate a new medication's safety and effectiveness in a broader population of patients. Phase 1 studies have already provided preliminary safety evaluations by that time, while Phase 2 trials provide a more comprehensive evaluation of the therapy's efficacy in treating edema.

The Phase III segment is expected to expand at the highest CAGR of 6.7% over the forecast period. Phase III involves pivotal studies intended to offer robust evidence of a treatment’s efficacy and safety in a large and diverse patient population. For the medication to receive regulatory approval, Phase 3 trial success is essential.

Participant Insights

Adults accounted for the largest revenue share of around 49.0% in 2022 and this segment is expected to maintain its position during the forecast period. Edema can result from various underlying diseases and have intricate symptoms. Adults with edema are ideal candidates for early-phase studies to test various treatment methods since they may have a longer history of the ailment and may represent a more heterogeneous population in terms of etiology and severity.

The geriatrics segment is expected to account for a significant share of the market in the coming years. The geriatric population is more likely to experience edema, in part because of changes to the body's lymphatic system, circulation, and fluid control systems caused by aging. This age group is a crucial target demographic for treatment trials due to the greater frequency of edema due to the growing older population.

Type Insights

The localized edema segment accounted for the largest revenue share of 63.5% in 2022 and is expected to maintain its position during the forecast period.The prevalence and intensity of localized edema in certain populations are expected to contribute to its prominence in clinical trials for specific regions or healthcare settings. Moreover, clinical trials examine the efficacy of a treatment for that particular condition by targeting specific types of edema, such as lymphedema or post-surgical edema.

On the other hand, systemic edema is also expected to account for a significant share of the market. Systemic edema is swelling that occurs all over the body and is often associated with underlying medical conditions such as heart failure, kidney disease, or liver disease. Thus, the increasing prevalence of such diseases is expected to boost segment growth in the coming years.

Sponsor Insights

The pharmaceutical companies segment dominated the edema clinical trial market in 2022 with a revenue share of over 51.0%.Pharmaceutical firms are at the forefront of drug development and are primarily concerned with investigating and developing new drugs to treat various medical ailments, including edema.In order to assess the security and effectiveness of their research pharmaceuticals for the treatment of edema, they take the initiative to support clinical studies.

The academic institutions segment is expected to expand at the highest CAGR of 5.93% over the forecast period.Academic medical centers often have access to a wide range of patients, including those with edema that is rare and difficult to treat. This diversity ensures the inclusion of a wider range of patients in clinical trials, enhancing the generalizability of results.

Regional Insights

In 2022, North America dominated the market with a revenue share of over 41% and is expected to expand rapidly in the forecast period. North America, particularly the U.S., has an advanced and robust research infrastructure, which includes academic institutions, research centers, and clinical trial sites. These institutions have the expertise, resources, and experience to effectively conduct clinical trials. Furthermore, U.S. government agencies, private foundations, and pharmaceutical companies provide substantial research funding. With this financial aid, clinical trials are initiated and supported in the region.

The Asia Pacific region is expected to advance at the highest CAGR of 6.13% across the forecast period. The growth of this regional market has been fueled mainly by the increasing prevalence of edema. Factors such as an aging population, increasing incidence of chronic diseases, and changes in lifestyle have contributed to the growing number of people affected by edema in the region. Moreover, the Asia-Pacific is home to a rapidly growing pharmaceutical industry, with countries such as China and India being important hubs for pharmaceutical manufacturing and research. As the pharmaceutical industry grows, more clinical trials are likely to be conducted to test new edema treatments that have been developed in the region.

Key Companies & Market Share Insights

Key companies in the market for edema clinical trials are undertaking various strategic initiatives such as new product launches, partnerships, mergers, and acquisitions to strengthen their market position. For instance, in December 2022, Oxurion NV announced that an Independent Data Monitoring Committee (IDMC) completed its planned interim analysis of the KALAHARI Phase 2, as a potential treatment for patients who respond sub-optimally to anti-VEGF standard of care for treatment of diabetic macular edema (DME). Some of the key companies in the global edema clinical trials market include:

• Otsuka Holdings

• Hoffmann-La Roche

• Novartis Pharmaceuticals

• Bayer

• Genentech, Inc.

• Biogen

• Johnson & Johnson

• Merck & Co., Inc.

• Sanofi S.A.

• AstraZeneca plc

• Bristol Myers Squibb Company

• GlaxoSmithKline plc

• AbbVie Inc.

Edema Clinical Trials Market Report Scope

Global Edema Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global edema clinical trials market report on the basis of phase, participant, sponsor, type, and region.

• Phase Outlook (Revenue, USD Million, 2018 - 2030)

  • Phase I

  • Phase II

  • Phase III

  • Phase IV

• Participant Outlook (Revenue, USD Million, 2018 - 2030)

  • Pediatrics

  • Adults

  • Geriatrics

• Sponsor Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical Companies

  • Academic Institutions

  • Government Bodies

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Systemic Edema

  • Localized Edema

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait